Literature DB >> 10197566

Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa.

L Sibulesky1, K C Hayes, A Pronczuk, C Weigel-DiFranco, B Rosner, E L Berson.   

Abstract

BACKGROUND: Vitamin A supplementation is being used successfully to treat some forms of cancer and the degenerative eye disease retinitis pigmentosa. The daily biological need for vitamin A is estimated to be 800 retinol equivalents (RE)/d (2667 IU/d) for adult women and 1000 RE/d (3300 IU/d) for adult men; doses > or = 7500 RE (> or = 25000 IU)/d are considered potentially toxic over the long term.
OBJECTIVE: We assessed the safety in adults of long-term vitamin A supplementation with doses above the daily biological need but <7500 RE (<25000 IU)/d.
DESIGN: Adults aged 18-54 y with retinitis pigmentosa but in generally good health (n = 146) were supplemented with 4500 RE (15000 IU) vitamin A/d for < or = 12 y (group A) and compared with a similar group (n = 149) that received 23 RE (75 IU)/d (trace group). Mean total consumption of vitamin A in group A was 5583 RE (18609 IU)/d (range: 4911-7296 RE/d, or 16369-24318 IU/d) and that in the trace group was 1053 RE (3511 IU)/d (range: 401-3192 RE/d, or 1338-10638 IU/d).
RESULTS: Patients in group A showed an 8% increase in mean serum retinol concentration at 5 y and an 18% increase at 12 y (P < 0.001); no retinol value exceeded the upper normal limit (3.49 micromol/L, or 100 microg/dL). Mean serum retinyl esters were elevated approximately 1.7-fold at 5 y and remained relatively stable thereafter. No clinical symptoms or signs of liver toxicity attributable to vitamin A excess were detected.
CONCLUSIONS: Prolonged daily consumption of <7500 RE (<25000 IU) vitamin A/d can be considered safe in this age group.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197566     DOI: 10.1093/ajcn/69.4.656

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  13 in total

Review 1.  Prevention and therapy in hereditary retinal degenerations.

Authors:  Dorothea Besch; Eberhart Zrenner
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

Review 2.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

3.  Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein.

Authors:  Rinku Baid; Arun K Upadhyay; Toshimichi Shinohara; Uday B Kompella
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

Review 4.  Vitamin A and fish oils for retinitis pigmentosa.

Authors:  Sobharani Rayapudi; Stephen G Schwartz; Xue Wang; Pamela Chavis
Journal:  Cochrane Database Syst Rev       Date:  2013-12-19

Review 5.  Delivery of retinoid-based therapies to target tissues.

Authors:  Alexander R Moise; Noa Noy; Krzysztof Palczewski; William S Blaner
Journal:  Biochemistry       Date:  2007-03-23       Impact factor: 3.162

6.  Association of Vitamin A Supplementation With Disease Course in Children With Retinitis Pigmentosa.

Authors:  Eliot L Berson; Carol Weigel-DiFranco; Bernard Rosner; Alexander R Gaudio; Michael A Sandberg
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

Review 7.  Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review.

Authors:  N Brito-García; T Del Pino-Sedeño; M M Trujillo-Martín; R M Coco; E Rodríguez de la Rúa; I Del Cura-González; P Serrano-Aguilar
Journal:  Eye (Lond)       Date:  2016-12-09       Impact factor: 3.775

Review 8.  Retinoids and Retinal Diseases.

Authors:  Philip D Kiser; Krzysztof Palczewski
Journal:  Annu Rev Vis Sci       Date:  2016-07-18       Impact factor: 6.422

9.  Does vitamin A prevent high-dose-methotrexate-induced D-xylose malabsorption in children with cancer?

Authors:  Ayhan Dagdemir; Hasan Yildirim; Yuksel Aliyazicioglu; Yilmaz Kanber; Davut Albayrak; Sabri Acar
Journal:  Support Care Cancer       Date:  2004-02-06       Impact factor: 3.603

10.  Current understanding of usher syndrome type II.

Authors:  Jun Yang; Le Wang; Hongman Song; Maxim Sokolov
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.